Ratings Outset Medical, Inc.

Equities

OM

US6901451079

Real-time Estimate Cboe BZX Other stock markets 01:27:47 2024-04-25 pm EDT			5-day change	1st Jan Change
2.345 ^USD	-8.04%		+4.22%	-56.65%

Apr. 17	Outset Medical and U.S. Renal Care Announce Multi-Year Agreement to Accelerate and Grow Home Dialysis Across the U.S	CI
Apr. 08	BTIG Initiates Outset Medical at Buy Rating With $6 Price Target	MT

Summary

The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
The company presents an interesting fundamental situation from a short-term investment perspective.

Strengths

Its core activity has a significant growth potential and sales are expected to surge, according to Standard & Poor's' forecast. Indeed, those may increase by 60% by 2026.
The company is one of the most undervalued, with an "enterprise value to sales" ratio at 0.32 for the 2024 fiscal year.
The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
Considering the small differences between the analysts' various estimates, the group's business visibility is good.
Historically, the company has been releasing figures that are above expectations.

Weaknesses

The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
The company has insufficient levels of profitability.
For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
For the past year, analysts have significantly revised downwards their profit estimates.
For the last few months, analysts have been revising downwards their earnings forecast.
The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.
The overall consensus opinion of analysts has deteriorated sharply over the past four months.
Over the past twelve months, analysts' consensus has been significantly revised downwards.
The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.

Ratings chart - Surperformance

Chart ESG Refinitiv

Sector: Advanced Medical Equipment & Technology

	1st Jan change	Capi.	ESG Refinitiv
OUTSET MEDICAL, INC.	-56.65%	132M	C-
THERMO FISHER SCIENTIFIC	+7.84%	220B	B
DANAHER CORPORATION	+6.64%	185B	B-
INTUITIVE SURGICAL, INC.	+10.28%	133B	B-
BOSTON SCIENTIFIC CORPORATION	+26.62%	107B	A-
SIEMENS HEALTHINEERS AG	-0.57%	62.91B	A-
EDWARDS LIFESCIENCES CORPORATION	+15.63%	53.34B	B+
SHENZHEN MINDRAY BIO-MEDICAL ELECTRONICS CO., LTD.	-1.89%	47.71B	B+
AGILENT TECHNOLOGIES, INC.	-2.33%	40.29B	A
GE HEALTHCARE TECHNOLOGIES INC.	+9.78%	39.57B	-

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Environment

Emissions

Innovation

Use of resources

Governance

CSR Strategy

Management

Shareholders

Controversy

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes